Structure’s obesity pipeline value prop ‘unperturbed,’ says H.C. Wainwright

Structure Therapeutics (GPCR) is expanding its obesity pipeline with ACCG-2671, a once-daily small molecule amylin agonist, setting the stage for a potential monotherapy and a dual combination therapy with GSBR-1290, H.C. Wainwright tells investors in a research note. The preclinical data showing comparable efficacy to cagrilintide is “impressive,” and Merck’s (MRK) “risky” deal does not perturb the firm’s thesis that small molecule platform and the pipeline is robust and differentiated, H.C. Wainwright adds.